Stock of the Day: It Seems Dynavax Technologies Corporation Will Go Up. Have Another Big Increase

Stock of the Day: It Seems Dynavax Technologies Corporation Will Go Up. Have Another Big Increase

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 344,909 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 78.07% since April 26, 2016 and is downtrending. It has underperformed by 83.33% the S&P500.
The move comes after 7 months positive chart setup for the $167.48M company. It was reported on Nov, 29 by Barchart.com. We have $5.10 PT which if reached, will make NASDAQ:DVAX worth $13.40M more.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 14. They expect $-0.86 EPS, down 22.86% or $0.16 from last year’s $-0.7 per share. After $-0.90 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -4.44% EPS growth.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The company was upgraded on Wednesday, August 12 by Zacks. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Neutral” rating by JP Morgan on Wednesday, April 27. The rating was initiated by RBC Capital Markets on Monday, November 30 with “Outperform”. The firm earned “Sector Perform” rating on Thursday, April 28 by RBC Capital Markets.

According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”

Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.26, from 1.02 in 2016Q1. The ratio increased, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
The Massachusetts-based Boston Limited Liability Company has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Metropolitan Life Insurance Ny, a New York-based fund reported 28,014 shares. Blackrock Fund Advsrs has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Boston Prns holds 0% or 123,378 shares in its portfolio. Teachers Advsr Inc last reported 62,022 shares in the company. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Lombard Odier Asset (Usa) Corporation reported 245,728 shares or 0.43% of all its holdings. Blackrock holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 3,490 shares. Wfg Advisors L P accumulated 65 shares or 0% of the stock. Glenhill Advsrs Limited Com holds 1.36% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1.29 million shares. Rhenman & Asset Ab holds 0.39% or 150,000 shares in its portfolio. Eventide Asset Management Limited Liability Company holds 0.22% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 250,000 shares. Moreover, Fmr Llc has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1.96M shares. Morgan Stanley reported 290,285 shares or 0% of all its holdings. Hatteras Funds Ltd has invested 0.86% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX).

More notable recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Seekingalpha.com which released: “Dynavax CRL: The FDA Is Buying Time” on November 28, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on November 14, 2016, Investorplace.com published: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” on November 14, 2016. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) were released by: Businesswire.com and their article: “SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit …” published on November 19, 2016 as well as 247Wallst.com‘s news article titled: “Why Dynavax Shares Are in Freefall” with publication date: November 14, 2016.

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment